Market News / Story
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with General…
BusinessWire ·
BusinessWire reports: PureTech Health plc ( ) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, today announced that the first patient has been dosed in a Phase 2a clinical trial in Australia evaluating GlyphAgo™ (SPT-320 or Glyph Agomelatine) in adults with generalized anxiety disorder (“GAD”) and sleep disturbance. The six-week trial is…